# EDGAR Filing Document

**Accession Number:** 0001434647
**File Stem:** 0000000000-23-002178
**Filing Date:** 2023-3
**Character Count:** 6347
**Document Hash:** fb82159dbda79775570cbfdb945fcf19
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-002178.hdr.sgml**: 20230526

**ACCESSION NUMBER**: 0000000000-23-002178

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230303

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZEVRA THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001434647
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 205894398
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 1180 CELEBRATION BOULEVARD, SUITE 103
- **CITY:** CELEBRATION
- **STATE:** FL
- **ZIP:** 34747
- **BUSINESS PHONE:** (321) 939-3416

**MAIL ADDRESS:**
- **STREET 1:** 1180 CELEBRATION BOULEVARD, SUITE 103
- **CITY:** CELEBRATION
- **STATE:** FL
- **ZIP:** 34747

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KEMPHARM, INC
- **DATE OF NAME CHANGE:** 20130530

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KEMPHARM INC
- **DATE OF NAME CHANGE:** 20080507
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001437749-23-004742

## Text-Extract

```

United States securities and exchange commission logo

                            March 3, 2023

       R. LaDuane Clifton
       Chief Financial Officer
       Zevra Therapeutics, Inc.
       1180 Celebration Boulevard, Suite 103
       Celebration, FL 34747

                                                        Re: Zevra Therapeutics,
Inc.
                                                            Preliminary Proxy
Statement on Schedule 14A
                                                            Filed February 27,
2023
                                                            File No. 001-36913

       Dear R. LaDuane Clifton:

              We have reviewed your filing and have the following comments. In
some of our
       comments, we may ask you to provide us with information so we may better
understand your
       disclosure.

               Please respond to these comments by providing the requested
information or advise us as
       soon as possible when you will respond. If you do not believe our
comments apply to your facts
       and circumstances, please tell us why in your response.

               After reviewing your response to these comments, we may have
additional comments.
       All defined terms have the same meaning as in the proxy statement.

       Preliminary Proxy Statement on Schedule 14A filed February 27, 2023

       When are stockholder proposals and director nominations due for next
year's annual meeting?,
       page 10

   1.                                                   Please provide the
disclosure required by Rule 14a-5(e)(4). See Item 1(c) of Schedule
                                                        14A and Rule 14d-19(b).
       Annex A. Information Concerning Participants in the Company's
Solicitation of Proxies, page A-
       1

   2.                                                   Please disclose the
information required by Item 5(b)(1)(iii) of Schedule 14A, which
                                                        requires you to
disclose whether or not any of the specified individuals have been
                                                        involved in any
proceedings.
 R. LaDuane Clifton
Zevra Therapeutics, Inc.
March 3, 2023
Page 2
General

3.       For proposals 2 and 3, please disclose the effect of an "ABSTAIN"
vote. See Item 21(b)
         of Schedule 14A.
        We remind you that the filing persons are responsible for the accuracy
and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

       Please direct any questions to Michael Killoy at (202) 551-7576 or
Christina Chalk at
(202) 551-3263.

FirstName LastNameR. LaDuane Clifton                        Sincerely,
Comapany NameZevra Therapeutics, Inc.
                                                            Division of
Corporation Finance
March 3, 2023 Page 2                                        Office of Mergers &
Acquisitions
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 3, 2023

R. LaDuane Clifton  
Chief Financial Officer  
Zevra Therapeutics, Inc.  
1180 Celebration Boulevard, Suite 103  
Celebration, FL 34747

**Re: Zevra Therapeutics, Inc.**  
**Preliminary Proxy Statement on Schedule 14A**  
**Filed February 27, 2023**  
**File No. 001-36913**

Dear R. LaDuane Clifton:

We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments. All defined terms have the same meaning as in the proxy statement.

Preliminary Proxy Statement on Schedule 14A filed February 27, 2023

When are stockholder proposals and director nominations due for next year's annual meeting?, page 10

1. Please provide the disclosure required by Rule 14a-5(e)(4). See Item 1(c) of Schedule 14A and Rule 14d-19(b).

Annex A. Information Concerning Participants in the Company's Solicitation of Proxies, page A-1

2. Please disclose the information required by Item 5(b)(1)(iii) of Schedule 14A, which requires you to disclose whether or not any of the specified individuals have been involved in any proceedings.

R. LaDuane Clifton
Zevra Therapeutics, Inc.
March 3, 2023
Page 2

General

3. For proposals 2 and 3, please disclose the effect of an "ABSTAIN" vote. See Item 21(b) of Schedule 14A.

We remind you that the filing persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please direct any questions to Michael Killoy at (202) 551-7576 or Christina Chalk at (202) 551-3263.

Sincerely,

Division of Corporation Finance
Office of Mergers & Acquisitions